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Background: Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water excretion. We
wanted to test the hypotheses that tolvaptan changes both renal handling of water and sodium and systemic
hemodynamics during basal conditions and during nitric oxide (NO)-inhibition with L-NG-monomethyl-arginine
(L-NMMA).
Methods: Nineteen healthy subjects were enrolled in a randomized, placebo-controlled, double-blind, crossover
study of two examination days. Tolvaptan 15 mg or placebo was given in the morning. L-NMMA was given as a
bolus followed by continuous infusion during 60 minutes. We measured urine output(UO), free water clearance
(CH2O), fractional excretion of sodium (FENa), urinary aquaporin-2 channels (u-AQP2) and epithelial sodium channels
(u-ENaCγ), plasma vasopressin (p-AVP), central and brachial blood pressure(cBP, bBP).
Results: During baseline conditions, tolvaptan caused a significant increase in UO, CH2O and p-AVP, and FENa was
unchanged. During L-NMMA infusion, UO and CH2O decreased more pronounced after tolvaptan than after
placebo (−54 vs.-42% and −34 vs.-9% respectively). U-AQP2 decreased during both treatments, whereas u-ENaCγ
decreased after placebo and increased after tolvaptan. CBP and bBP were unchanged.
Conclusion: During baseline conditions, tolvaptan increased renal water excretion. During NO-inhibition, the more
pronounced reduction in renal water excretion after tolvaptan indicates that NO promotes water excretion in the principal
cells, at least partly, via an AVP-dependent mechanism. The lack of decrease in u-AQP2 by tolvaptan could be explained
by a counteracting effect of increased plasma vasopressin. The antagonizing effect of NO-inhibition on u-ENaC suggests
that NO interferes with the transport via ENaC by an AVP-dependent mechanism.
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Vasopressin (AVP) stimulates translocation of aquaporin2
water channels (AQP2) to the apical plasma membrane,
thereby increasing water permeability in the collecting
ducts [1-3]. In addition to its effects on water permeability
AVP also stimulate sodium absorption in the collecting
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article, unless otherwise stated.channels (ENaC) [4,5]. In addition to AVP, recent studies
have suggested that nitric oxide (NO) also has an effect on
the translocation of AQP2 to form water channels [6-8].
The synthesis of NO is inhibited by L-NG-monomethyl-ar-
ginine (L-NMMA), a competitive inhibitor of NO. Infusion
of L-NMMA causes reduced renal plasma flow, reduced
renal excretion of sodium, renal renin concentration and
increased blood pressure [7,9]. However, the effects of NO
inhibition on the translocation of AQP2 water channels
during inhibition of the vasopressin 2 receptor (V2R) have
not been examined.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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vation of V2R by AVP thereby inhibiting insertion of AQP2
water channels in the collecting ducts, and thus stimulating
aquaresis, an electrolyte-free water excretion [2,10-19]. We
wanted to test the hypotheses that short-term tolvaptan
treatment would decrease renal absorption of water and so-
dium during basal conditions, and that this effect would be
antagonized by NO-inhibition. In addition, we wanted to
test whether the effects of tolvaptan on the central blood
pressure, vasopressin in plasma and the activity of the
renin-angiotensin-aldosterone system antagonized the ef-
fects on renal water and sodium handling.
Selctive V2R antagonism may be therapeutically useful
for the treatment of conditions with impaired water excre-
tion, and consequently dilutional hyponatremia, associated
with the syndrome of inappropriate secretion of antidiure-
tic hormone, congestive heart failure and cirrhosis. In-
creased knowledge of the mechanisms involved in the
regulation of water and sodium may improve future treat-
ment of hyponatremia in these patients.
We conducted a randomized, placebo-controlled, double-
blinded, crossover study in healthy subjects to measure the
effects of tolvaptan on (1) renal handling of water and so-
dium (glomerular filtration rate (GFR), urine output (UO),
free water clearance (CH2O), u-AQP2, u-EnaCγ, fractional ex-
cretion of sodium (FENa), (2) plasma concentrations of renin
(PRC), angiotensin II (p-AngII), aldosterone (p-Aldo) and
p-AVP, (3) hemodynamics (brachial blood pressure (bBP),
central blood pressure (cBP), pulse wave velocity (PWV) and
augmentation index (AI)), during baseline conditions and




Healthy subjects were enrolled with the inclusion criteria
1) age between 18–40 yrs., 2) men and women, 3) non-
smokers, 4) BMI between 18.5 and 30 kg/m2.
Exclusion criteria
Exclusion criteria included 1) arterial hypertension (bBP >
140 mmHg systolic and/or > 90 mmHg diastolic), 2) history
or clinical signs of neoplastic disease or disease of the heart,
lungs, kidneys or endocrine organs, 3) drug or alcohol
abuse (I.e. >14 objects a week for women and 21 for men),
4) medical treatment except oral contraceptives, 5) preg-
nancy or breast-feeding, 6) significant laboratory abnormal-
ities in the screening test of blood samples (I .e. abnormal
haemoglobin, white cell count, plasma sodium, plasma po-
tassium, plasma creatinine, plasma albumin, plasma biliru-
bin, plasma alanine aminotransferase or serum cholesterol)
and urine samples (I.e. albuminuria or glucosuria), 7) ab-
normal electrocardiogram, 8) blood donation less than one
month prior to the study.In fertile women contraceptive treatment must be used
during and after the after the study period (I.e. p-pills,
spiral, depot injection of gestagen, sub dermal implant-
ation, hormonal contraceptive vaginal ring and transder-
mal contraceptive patch).
Withdrawal criteria were development of one or more of
the exclusion criteria, bBP increase above 180/105 mmHg
during infusion of L-NMMA, withdrawal of consent or lack
of compliance.
Study design
We performed a randomized, crossover double-blinded,
placebo- controlled trial. The trial consisted of two treat-
ment periods, placebo or tolvaptan, with an intermediate
wash- out period of at least two weeks to eliminate any car-
ryover effects.
Number of subjects
CH2O was used as the main effect variable. With a minimal
relevant difference of 6 ml/min with an estimated standard
deviation (SD) of 4 ml/min 18 subjects were needed using
a level of significance of 5% and a statistical power of 80%.
Due to possible drop outs 20 subjects were included.
Recruitment
Healthy subjects were recruited by advertising in public
institutions and private companies.
Ethics
This study was approved by the Regional Committee on
Health Research Ethics (j. no. M-201223912). The study
was conducted in conformity with the principles of the
declaration of Helsinki. Written informed consent was
obtained from all subjects.
Effect variables
The primary effect variable was CH2O. The secondary effect
variables were 1) renal function (GFR, UO, u-AQP2, u-
ENaCγ, FENa), 2) hemodynamics (bBP, cBP, PWV, AI) and
3) vasoactive hormones (PRC, p-ANG II, p-Aldo, p- AVP).
Diet
Four days prior to each treatment period all subjects
ingested a standardized diet of 11.000 KJ. The diet was
composed of 55% carbohydrates, 15% proteins and 30%
fat following general dietary guidelines. The sodium con-
tent was 150 mmol per day. No additional sodium or
other spices was allowed. The daily fluid intake was
2.5 L. No alcohol intake was allowed.
Experimental procedure
The examinations were conducted in Medical Research
from 7:45 AM to 1:00 PM. The procedures were identical
on the two examination days. On the morning of each
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15 mg at 6.00 AM. Prior to each examination day a 24-
hours urine was collected and a fasting period of eight
hours was performed.
An intravenous catheter was placed in each arm to collect
blood samples and infuse the 51Cr-EDTA. At 8:00 AM and
every 30 minutes, an oral water load of 175 ml was given.
BP was measured every 30 minutes from 8:30 AM to
1:00 PM. A bolus infusion of L-NMMA 4.5 mg/kg was
given at 11:00 AM, followed by continuous infusion
(3 mg/kg/hour) during one hour. The dose was based on
results from a dose-finding study made by our team in
healthy subjects [9]. During infusion of L-NMMA BP
was measured every 5 minutes, and every 15 minutes
after infusion of L-NMMA.
Blood samples were drawn every 30 minutes from 8:30
to 1:00 PM and were analyzed for p-Na, p-osm, p-
creatinine, p-albumin and p- 51Cr-EDTA. Blood samples
were drawn for measurement of PRC, p-Aldo, p-Ang II
and p-AVP every 60 minutes; at 11:00 AM (baseline), at
12:00 AM (after end of L-NMMA infusion) and at
1:00 PM (60 minutes after end of L-NMMA infusion).
Urine samples were collected by voiding in standing or
sitting position every 30 minutes from 9:30 AM to
1:00 PM after collecting BP measurements and blood sam-
ples. Otherwise subjects were kept in a supine position in
a quiet, temperature-controlled room (22 – 25°C). Base-
line period were means of the first three clearance periods.
The urine samples were analyzed for osmolality (u-osm),
creatinine (u-creatinine), sodium (u-Na), u-AQP2, u-EnaCγ
and 51Cr-EDTA (u-51Cr-EDTA).
Applanation tonometry with SphygmoCor was per-
formed from 10:40 to 11:40 AM.
Measurements
Renal function
GFR were measured using the constant infusion clear-
ance technique with 51Cr-EDTA as reference substance.
CH2O was determined using the formula CH2O =UO-Cosm,
where Cosm is the osmolar clearance.
Clearance (C) of substance X was calculated as CX =
UX/(PX x UO), where UX denotes concentration of x in
urine, PX denotes concentration of x in plasma, and UO is
urine excretion rate.
Fractional exretion of sodium and potassium were de-
termined according to the following formula FEx = (uX *
V/pcreatinine/pX* ucreatinine)/GFR, where uX and pX
are urine and plasma concentrations respectively, and V
is the flow in ml/min during GFR measurement.
Urinary excretion of AQP2 and ENaCγ
Urine samples were kept frozen at −20°C until assayed.
U-AQP2 was measured by radioimmunoassay as previ-
ously described [20,21]. Antibodies were raised in rabbitsto a synthetic peptide corresponding to the 15 COOH-
terminal amino acids in human AQP2 to which was
added an NH2-terminal cystein for conjugation and af-
finity purification. Minimal detection level was 34 pg/
tube/tube. The coefficients of variation were 11.7% (in-
ter-assay) and 5.9% (intra-assay). U-ENaCγ was mea-
sured by radioimmunoassay as previously described [22].
Antibodies were raised against the synthetic ENaCγ pep-
tide in rabbits and affinity purified as described previ-
ously [23]. Minimal detection level was 48 pg/tube. The
coefficients of variation were 14% (inter-assay) and 6.7%
(intra-assay). The anti-AQP2 antibody was a gift from
Soeren Nielsen, The Water and Salt Research Center,
Institute of Anatomy, Aarhus University, Denmark.
Vasoactive hormones in plasma
Blood samples for measurements of vasoactive hormones
were centrifuged for 10 minutes at 2200 G and 4°C. Plasma
was separated from blood cells and kept frozen until
assayed. PRC was determined using an immunoradiometric
assay from CIS Bio International, Gif-Sur-Yvette Cedex,
France. Minimal detection level was 1 pg/ml. The coeffi-
cients of variation were 0.9-3.6% (intra-assay) and 3.7-5.0%
(inter-assay) in the range of 4–263 pg/ml. Aldo was deter-
mined by RIA using a kit from Demeditec Diagnostics
GmbH, Kiel, Germany. Minimal detection level was 25
pmol/l. The coefficients of variation were 9.0% (inter-assay)
and 8.5% (intra-assay). Ang II and AVP were extracted from
plasma with C18 Sep-Pak (Water associates, Milford, MA,
USA), and subsequently determined by radioimmunoassay
[24,25]. The antibody against Ang II was obtained from the
Department of Clinical Physiology, Glostrup Hospital,
Denmark. Minimal detection level was 2 pmol/L. The coef-
ficients of variation were 12% (inter-assay) and 8% (intra-
assay). The antibody against AVP was a gift from Professor
Jacques Dürr, Miami, Fl, USA. Minimal detection level was
0.2 pmol/L. The coefficients of variation were 13% (inter-
assay) and 9% (intra-assay).
Brachial and central blood pressure
Bbrachial BP pressure was measured using an oscillometer
(Omron 705IT) and recorded in accordance with recom-
mendations from the European Society of Hypertension.
Brachial systolic and diastolic blood pressure was recorded
as the average of duplicate measures. Central BP was mea-
sured using applanation tonometry. Recordings of PWA
and carotid-femoral PWV were obtained by applanation
tonometry (SphygmoCor® CPV system®, AtCor Medical,
Sydney, Australia) as double-recordings by a trained obser-
ver. Only duplicate recording meeting the quality require-
ments were included in the final analysis. An operator
index of 80 or more was required to accept recordings of a
peripheral pulse-wave form. The variation was measured in
10 healthy subjects. The participants rested for 15 minutes
Table 1 Urine output (UO), free water clearance (CH2O),
urinary excretion of AQP2 (u-AQP2), ENaC (u- ENaCγ),
sodium (u-Na) and potassium (u-K) during a 24-hours urine
collection before each examination day in a randomized,
placebo-controlled, double-blind, crossover study of 19
healthy subjects
Before each examination day p
(paired t-test)Placebo Tolvaptan
UO (ml/24 h) 1969 ± 448 2025 ± 514 0.51
CH2O (ml/min) −0.46 ± 0.61 −0.47 ± 0.57 0.99
U-AQP2 (ng/min) 1.10 ± 0.32 1.12 ± 0.27 0.57
U-ENaCγ (pg/min) 716 ± 374 705 ± 376 0.87
U-Na (mmol/24 h) 103 ± 11 101 ± 8 0.652
U-K (mmol/24 h) 55 ± 19 51 ± 14 0.472
Data are shown as means with ± SD. Paired t-test was used for comparison
between groups.
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blood pressure, PWA and PWV. For intra-observer vari-
ation, five measurements were performed by each observer
in all ten subjects. For each subject, a coefficient of vari-
ation (CV) was calculated for each observer. The mean
values of CV’s regarding the ten measurements for each ob-
server were 4-6% for PWV (Observer 1: 6.4%, Observer 2:
3.8%, and Observer 3: 5.6%), and in the same range for
PWA (Observer 1: 4.3%, Observer 2: 5.0%, and Observer 3:
5.7%). The inter-observer variation was calculated as means
of CV of the average values obtained by the three observers
for ten subjects (PWV: 7.5%, PWA: 5.6%).
Routine analyses
Sodium, albumin, hemoglobin and glucose were mea-
sured by routine methods in Department of Clinical
Biochemistry, Holstebro Hospital.
Statistics
Statistical analyses were performed using IBM SPSS statis-
tics version 20.0.0 (SPSS Inc., Chicago, IL, USA). General
Linear Model Repeated Measures was used for compari-
son between and within subjects to test differences
between placebo and tolvaptan treatment group at base-
line, during and after infusion of L-NMMA. Post-hoc
Bonferoni test was used to compare differences within
groups at baseline and during L-NMMA infusion, and at
baseline and after L-NMMA infusion.
Paired sample t-test was performed to compare differ-
ences between treatment groups at baseline, during and
after infusion of L-NMMA. Statistical significance was at
< 0.05 in all analyses. Data with normal distribution are
reported as means ± SD. Non-parametric test was per-
formed for data with non-normal distribution, and are re-
ported as medians ± interquartile range or medians with
25th and 75th percentiles.
Results
Demographics
We allocated 29 subjects to the study. Ten of the partici-
pants were excluded due to lack of compliance (2), diffi-
culties to gain intravenous access (3), arterial hypertension
and/or medication (2), withdrawal of consent (3). Nine-
teen participants completed the study, 12 females and 7
males, with a median age of 25 ± 4 years, weight 72.3 ±
13.4 kg, body mass index 24 ± 3.4 kgm−2. p-sodium 141 ±
1.7 mmol/L, p-potassium 3.8 ± 0.3 mmol/L, p-creatinine
77.1 ± 18.7 μmol/L. Systolic brachial blood pressure (SBP)
122 ± 9 mmHg, diastolic brachial blood pressure (DBP)
70 ± 7 mmHg.
Urine collection before the examination day
Table 1 shows the values of the 24 hours urine collection
before each examination day. There were no significantdifferences in UO, CH2O, u-AQP2, u-ENaCγ and u-Na
between the two treatment periods.
GFR
At baseline, GFR was the same after both treatments
(Table 2). In response to L-NMMA infusion, GFR was
significantly reduced during both treatments, but no
differences were found between treatments. The relative
decreases in GFR were similar after placebo and tolvap-
tan (Figure 1).
Tubular handling of water and sodium
Absolute values of UO and CH2O after treatment with pla-
cebo and tolvaptan are shown in Table 2. The relative
changes after L-NMMA infusions are shown in Figure 1. At
baseline, UO and CH2O were significantly higher during tol-
vaptan treatment compared with placebo (p = 0.009 and
p = 0.002, respectively). During L-NMMA infusion, UO and
CH2O were significantly decreased after both treatments.
However, UO and CH2O were approximately 30% lower in
the first 30 minutes (Period: 90–120 min) during L-NMMA
infusion in the placebo group compared to the tolvaptan
group (p = 0.026 and 0.009 respectively). During the follow-
ing 30 minutes (period: 120–150 min.), UO and CH2O were
similar. The relative decrease in CH2O and UO were signifi-
cant within both treatments, but the relative decrease in UO
and CH2O were significantly more pronounced in the tolvap-
tan group (p = 0.018 and p = 0.008 respectively).
At baseline, Table 2 shows that FENa was similar dur-
ing both treatments. During L-NMMA infusion, FENa
was significantly decreased and to the same extent dur-
ing both treatments.
U-AQP2 and U-ENaC
During baseline conditions, u-AQP2 was the same after
tolvaptan and placebo (Table 2). In response to L-NMMA
Table 2 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on GFR (51-CrEDTA-clearance),
urinary output (OU), free water clearance (CH2O), urinary aquaporin2 excretion rate (u-AQP2), urinary ENaCγ excretion
rate (u-ENaCγ) and fractional excretion of sodium (FENa) in a randomized, double-blind, placebo-controlled, crossover
study of 19 healthy subjects
Periods Baseline L-NMMA Post infusion P
(GLM-within)90-120 min 120-150 min 150-180 min 180-210 min
51Cr-EDTA-clearance (ml/min/1.73 m2)
Placebo 99 ± 5 93 ± 10*** 92 ± 8*** 94 ± 8*** 97 ± 9
0.522
Tolvaptan 97 ± 9 91 ± 12*** 93 ± 9*** 90 ± 12*** 94 ± 12
p (GLM between) 0.527
p (paired t-test, between) 0.403 0.533 0.583 0.118 0.197
UO (ml/min)
Placebo 7.4 ± 1.3 3.0 ± 1.2*** 4.2 ± 1.3*** 4.9 ± 1.2*** 6.3 ± 1.1
<0.0001
Tolvaptan 8.9 ± 1.7 4.3 ± 1.8*** 4.2 ± 1.8*** 4.9 ± 1.3*** 5.7 ± 1.6
p (GLM between) 0.230
p (paired t-test, between) 0.009 0.026 0.965 0.861 0.124
CH2O (ml/min)
Placebo 4.6 ± 1.1 2.9 ± 1.0*** 3.9 ± 1.2*** 4.6 ± 1.0*** 5.9 ± 1.0
<0.0001
Tolvaptan 5.8 ± 1.1 4.4 ± 1.8* 4.0 ± 1.6* 3.9 ± 1.2 5.2 ± 1.4
p(GLM between) 0.185
p (paired t-test, between) 0.002 0.009 0.756 0.063 0.097
u-AQP2 (ng/min)
Placebo 1.30 ± 0.27 1.04 ± 0.36* 0.99 ± 0.19*** 1.06 ± 0.24*** 1.11 ± 0.20
0.444
Tolvaptan 1.32 ± 0.28 1.08 ± 0.39 1.04 ± 0.23*** 1.17 ± 0.32*** 1.10 ± 0.21
p (GLM between) 0.614













(281; 379) (361; 492) (322; 537)
p (Wilcoxon’s signed rank test, between) <0.001 0.355 0.227
FENa
Placebo 1.17 ± 0.62 0.77 ± 0.35* 0.78 ± 0.37* 1.12 ± 0.41 1.07 ± 0.35 0.945
Tolvaptan 1.29 ± 0.45 0.89 ± 0.34* 0.87 ± 0.32* 1.22 ± 0.30 1.18 ± 0.30
p (GLM between) 0.328
p (paired t-test, between) 0.326 0.073 0.073 0.198 0.200
Data are shown as mean with ± SD or medians with 25th and 75th percentiles in parentheses. General linear model (GLM) with repeated measures was performed
for comparison within the group and intervention as between subject factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min
vs baseline and post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at
baseline and during infusion period 90–150 min, and at baseline and post infusion period 150 – 210 min. *p < 0.05; **p < 0.001;***p < 0.0001.
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extent after both treatments. The relative changes in u-
AQP2 were similar during and after L-NMMA infusion in
the treatment groups (Figure 1).
U-ENaCγ was approximately 33% lower during tolvaptan
treatment compared to placebo at baseline (p = 0.002).During L-NMMA infusion, u-ENaCγ was reduced by L-
NMMA infusion after placebo, whereas a significant
increase was measured after tolvaptan (p < 0.001).
U-ENaCγ decreased 9.76 ± 23.94% after placebo and in-
creased 33.40 ± 21.86% after tolvaptan in the L-NMMA
infusion period (Figure 2).
Figure 1 Relative changes in GFR (A), CH2O (B), UO (C) and u-AQP2 (D) during NO-inhibition. Values are mean ± SEM. General linear model
(GLM) with repeated measurements was performed for comparison within the group (δ) and interventions as between (Δ) subject factor. Paired
t-test or Wilcoxon signed rank test (#) was performed for comparison within treatment group at baseline vs during infusion period 90–150 min,
and baseline vs post infusion 150–210 min. #/Δ p < 0.05; δδδ p < 0.0001.
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During baseline conditions, p-Na, p-Osm and p-K were sig-
nificantly higher in the tolvaptan group compared to the
placebo group (Table 3). In response to L-NMMA infusion,
p-Na and p-Osm remained significantly higher duing tol-
vaptan treatment compared with placebo, whereas no dif-
ferences were measured in p-K between the treatments.Vasoactive hormones
At baseline, PRC, p-AngII and P-Aldo were the same after
tolvaptan and placebo (Table 4). PRC was significantly de-
creased during inhibition of NO synthesis in both treat-
ment groups (p < 0.001), but no difference was observed
between groups. P-AngII fell significantly only in thetolvaptan group (p = 0.001), but tended to fall also during
placebo. P-Aldo was unchanged during both treatments.
A highly significant and sustained 3–fold increase in p-
AVP was measured during treatment with tolvaptan com-
pared to placebo (Placebo: 0.20 ± 0.15 vs. 0.70 ± 0.45 pg/ml,
p <0.0001). P-AVP did not change from baseline levels dur-
ing L-NMMA infusion.
Effects of L-NMMA on brachial bloodpressure
Within the first five minutes of L-NMMA bolus infusion,
BP peaked in both groups and then gradually declined
over the first 20 min of infusion (Figure 3). During the
remaining 40 minutes of infusion, BP changes were similar
in both groups (p = 0.221 for SBP and p = 0.678 for DBP
with GLM). An average of the six measurements from the
Figure 2 Relative changes in FENa (E) and u-ENaCγ (F) during inhibition of the NO system. Values are mean ± SEM. General linear model
(GLM) with repeated measurements was performed for comparison within the group (δ) and interventions as between (Δ) subject factor. Paired
t-test or Wilcoxon signed rank test (#) was performed for comparison within treatment group at baseline vs during infusion period 90–150 min,
and baseline vs post infusion 150–210 min. # p < 0.05; ## p < 0.001.
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to baseline blood pressure. L-NMMA caused a signifi-
cant increase in SBP (4 ± 3 mmHg in placebo vs. 3 ±
2 mmHg in tolvaptan) and bDBP (7 ± 6 mmHg in pla-
cebo vs. 6 ± 7 mmHg in tolvaptan). No significant
differences were found between treatments (p = 0.374
for SBP and p = 0.606 for DBP).Table 3 Effect of tolvaptan at baseline and during inhibition




0-90 min 90-120 min 12
p-sodium (mmol/l)
Placebo 140 ± 2 139 ± 1
Tolvaptan 143 ± 2 143 ± 2
P (Wilcoxon’s signed rank test) 0.001 0.001
p- osm (mosm/kg)
Placebo 285 ± 3 285 ± 4
Tolvaptan 291 ± 3 291 ± 3
p (GLM between) <0.0001
p (paired t-test) <0.001 <0.001
p-potassium (mmol/l)
Placebo 3.8 ± 0.2 3.8 ± 0.3
Tolvaptan 3.9 ± 0.2 3.9 ± 0.2
p (Wilcoxon’s signed rank test) 0.028 0.117
Data are shown as mean with ± SD or medians with ± interquartile range. General li
within the group and intervention as between subjects factor. Post-hoc Bonferoni t
post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test
infusion period 90–150 min, and at baseline vs post infusion period 150 – 210 min.Effects of tolvaptan on brachial blood pressure
At baseline, SBP and DBP did not differ between treatments,
whereas pulse rate was significantly higher in the placebo
group (Table 5). L-NMMA infusion induced a significant
increase in both SBP and DBP during both treatments, but
differences were measured between treatments. During L-
NMMA infusion, pulse rate fell similarly in both groups.of the nitric oxide system on plasma concentration of
d, placebo-controlled, double-blind, crossover study of
Post infusion p
(GLM-within)0-150 min 150-180 min 180-210 min
139 ± 2** 139. ± 2 138 ± 2**
0.272
141 ± 3** 141 ± 2 141 ± 2*
0.002 0.001 0.001
283 ± 4** 284 ± 4** 283 ± 4***
0.352
291 ± 3 291 ± 3 290 ± 3
<0.001 <0.001 <0.001
3.9 ± 0.3 3.9 ± 0.2 3.8 ± 0.1
0.325
4.0 ± 0.2 4.0 ± 0.1 4.0 ± 0.1
0.272 0.929 0.430
near model (GLM) with repeated measures was performed for comparison
est (*) was used for comparison of infusion period 90–150 min vs baseline and
was used for comparison between treatment group at baseline vs during
*p < 0.05; **p < 0.001;***p < 0.0001.
Table 4 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on plasma concentrations of
renin(PRC), angiotensin II (P-AngII), aldosterone (P-aldo) and vasopressin (P-AVP) in a randomized, placebo-controlled,
double-blind, crossover study of 19 healthy subjects
Periods
Baseline L-NMMA Post infusion P
(GLM-within)11:00 AM 12:00 AM 1:00 PM
PRC(pg/ml)
Placebo 8.1 ± 4.3 6.1 ± 3.2** 5.9 ± 3.2**
0.670
Tolvaptan 9.9 ± 6.8 7.5 ± 4.6** 7.5 ± 5.4**
p (GLM between) 0.305
p (paired t-test, between) 0.101 0.050 0.038
P-AngII (pg/ml)
Placebo 9.5 ± 4 8.6 ± 3.7 8.0 ± 3.3*
0.156
Tolvaptan 11.9 ± 6.2 9.4 ± 4.6* 9.5 ± 5.1*
p (GLM between) 0.686
p (paired t-test, between) 0.094 0.403 0.117
P- Aldo (pmol/L)
Placebo 70 ± 2 75 ± 2 64 ± 2
0.949
Tolvaptan 71 ± 2 78 ± 2 66 ± 1
p (GLM between) 0.899
p (paired t-test, between) 0.962 0.785 0.840
P- AVP (pg/ml)
Placebo 0.20 ± 0.15 0.20 ± 0.15 0.20 ± 0.20
Tolvaptan 0.70 ± 0.45 0.70 ± 0.55 0.70 ± 0.60
p (Wilcoxon’s signed rank test, between) <0.001 <0.001 <0.001
Data are shown as mean with ± SD or medians with ± interquartile range. General linear model (GLM) with repeated measures was performed for comparison
within the group and intervention as between subject factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min vs baseline and
post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at baseline vs during
infusion period 90–150 minu, and at baseline vs post infusion period 150 – 210 min. *p < 0.05; **p < 0.001;***p < 0.0001.
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At baseline, no difference was observed in PWV, cBP and
AI between tolvaptan and placebo (Table 6). During L-
NMMA infusion, PWV increased significantly in the tol-
vaptan group (p = 0.012), whereas it remained unchanged
in the placebo group. Systolic cBP and AI increased in the
same way in the tolvaptan group, but remained unchanged
in the placebo group. The changes were similar between
groups. During l-NMMA infusion diastolic cBP increased
significantly after both treatments.
Discussion
In the present study, we examined the effect of short-term
treatment with tolvaptan on renal tubular function, vaso-
active hormones and central hemodynamics, during basal
conditions and during inhibition of the NO-system with
L-NMMA in healthy subjects. During baseline conditions,
tolvaptan increased UO and CH2O. An expected decrease
in u-AQP2 was not measured and counteracted by a
threefold increase in p-AVP. Tolvaptan did not change
FENa and decreased u-ENaCγ as expected. During NO-
inhibition, UO and CH2O decreased after both treatments,but the decrease after tolvaptan was significantly more pro-
nounced than after placebo. In contrast, FENa was de-
creased similarly after both tolvaptan and placebo during
NO-inhibition. U-AQP2 decreased to the same extent after
both treatments, whereas u-ENaCγ decreased after tolvap-
tan and increased after placebo. The present study is the
first randomized, double-blinded, placebo-controlled cross-
over trial to measure the effect of tolvaptan on renal tubular
function, vasoactive hormones and central hemodynamics
during inhibition of the NO-system with L-NMMA. The
dose of L-NMMA was based on a previous dose–response
study [9]. We demonstrated an infusion method in which a
steady NOS inhibition was obtained, and in a dose
dependent manner L-MNNA infusion increased blood
pressure.
Renal handling of water
During baseline conditions, UO and CH2O increased
after tolvaptan as expected. However, after NO- inhibition,
the decrease in UO and CH2O was significantly more pro-
nounced after tolvaptan than placebo, but p-AVP was un-
changed. Thus, tolvaptan seemed to potentiate the reduction
Figure 3 Effect of tolvaptan on bBP during inhibition of the NO system. Values are mean ± SEM. Baseline brachial blood pressure (bBP) was
defined as a mean of the four measurements 30 min prior to L-NMMA infusion. A stable bBP was achieved for the last 40 min of L-NMMA infusion.
A mean of the six measurements from last 40 minutes of L-NMMA infusion was used to calculate changes from baseline. Post-hoc Bonferoni test was
used for comparison of the mean of the last 40 min of infusion vs. baseline (p = 0.011 in placebo vs p < 0.0001 in tolvaptan). Paired t-test was
performed for comparison of the last 40 min of infusion vs. baseline between treatment groups.
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explained by interference of NO with renal water excre-
tion in the principal cells in the distal part of the neph-
ron by a partly AVP-dependent mechanism, resulting in
an increase in renal water excretion. This is a new and ori-
ginal observation. However, we cannot exclude an impact
of NO on water excretion through an AVP-dependent
mechanism, too.
In the distal part of the nephron, water is absorbed via
AQP2 [1]. AVP exhibits a short-term effect through the
cAMP pathway to regulate translocation of preformed
AQP2 proteins from cytosolic vesicles to the apical plasma
membrane of the collecting duct principal cells, thereby
increasing water permeability across the collecting duct
[3]. In addition, AVP exhibits a long-term effect through
its action on the cAMP-responsive element in the AQP2
promoter site, thereby enhancing the AQP2 gene expres-
sion. This long-term regulation determines the abundance
of AQP2 water channels available for the modulation of
the apical membrane's water permeability [1,26,27]. This
is in agreement with results in several experimental and
clinical studies, which have demonstrated that treatment
with vasopressin or 1-desamino-8-D-arginine-vasopressin
(dDAVP), a V2R agonist, enhanced translocation of AQP2
water channels to the apical membrane and results in
water retention [2]. Surprisingly, during baseline condi-
tions, u-AQP2 was the same after tolvaptan and placebo.
However, the lack of decrease in u-AQP2 after tolvaptan
can be attributed to the high level of p-AVP, which coun-
teracts the effect of tolvaptan on the V2 receptor. Anotherexplanation might be that the baseline period was too
short to reflect a decrease in u-AQP2 after tolvaptan.
During NO inhibition, u-AQP2 was suppressed to the
same extent both after tolvaptan and placebo. Conflict-
ing results have been reported regarding the effect of
NO on AQP2 water channels. Some results suggested
an effect via a cGMP dependent pathway, and others via
an AVP dependent mechanism [28-30]. We demon-
strated that u-AQP2 fell in response to NO inhibition
during both treatments. From the placebo treatment,
our results strongly support the assumption that L-
NMMA decreased translocation of AQP2 channels to the
apical membrane, and thereby reduced water absorption
via reduced water transport via the AQP2 water channels.
Tolvaptan treatment, however, potentiated the effect of L-
NMMA on UO and CH2O, and thereby increased the
absorption of water significantly. This means that the in-
crease in renal water excretion induced by NO seems to
be at least partly mediated by an AVP-dependent mechan-
ism. During NO-inhibition, the lack of differences in
uAQP2 between tolvaptan and placebo can be attributed
to the fact that u-AQP2 was suppressed to a low level dur-
ing both treatments by L-NMMA, and a difference be-
tween the two treatments could not be detected during
this condition.
Renal handling of sodium
During baseline conditions, FENa was the same after tol-
vaptan and placebo. L-NMMA reduced FENa to the same
extent after both treatments. The role of AVP in renal
Table 5 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on brachial systolic- and
diastolic blood pressure (SBP and DBP), and pulse rate in a randomized, placebo-controlled, double-blind, crossover
study of 19 healthy subjects
Periods Baseline L-NMMA Post infusion p
(GLM-within)0-90 min 90-120 min 120-150 min 150-180 min 180-210 min
SBP (mmHG)
Placebo 112 ± 8 113 ± 9 115 ± 8* 115 ± 9* 116 ± 10*
0.170
Tolvaptan 112 ± 11 115 ± 9* 116 ± 9* 116 ± 10* 114 ± 9
p (GLM between) 0.876
p (paired t-test, between) 0.833 0.117 0.272 0.929 0.430
DBP (mmHg)
Placebo 61 ± 5 68 ± 6*** 67 ± 6*** 67 ± 5* 65 ± 7
0.688
Tolvaptan 63 ± 5 69 ± 7*** 68 ± 6*** 67 ± 6 66 ± 7
p(GLM between) 0.606
p (paired t-test, between) 0.049 0.467 0.259 0.907 0.454
Pulse rate (BPM)
Placebo 57 ± 10 52 ± 9*** 53 ± 9*** 55. ± 11*** 58 ± 12***
0.889
Tolvaptan 55 ± 10 50 ± 9*** 51 ± 9*** 53 ± 10*** 56 ± 11*
p (GLM between) 0.527
p (paired t-test, between) 0.016 0.022 0.007 0.013 0.003
Data are shown as mean with ± SD or medians with ± interquartile range. General linear model (GLM) with repeated measures was performed for comparison
within the group and intervention as between subjects factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min vs baseline and
post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at baseline vs during
infusion period 90–150 min, and at baseline vs post infusion period 150–210 min. *p < 0.05; **p < 0.001;*** p < 0.0001.
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creased water permeability of the luminal membrane
through its action on AQP2, but also increased sodium
absorption by of ENaC [2,5]. According to studies in rats,
the effect of AVP on ENaC depended on the plasma con-
centration of AVP [2]. Within the physiologic range, AVP
promoted antinatriuresis in the distal nephron, mediated
by V2R. In healthy subjects, Blanchard et al. [31] showed
that the antinatriuretic effect of dDAVP was amiloride
sensitive, and thus related to vasopressin’s stimulatory ef-
fect on sodium absorption to be mediated by ENaC. We
found a lower u-ENaCγ during tolvaptan treatment during
baseline conditions, which is in agreement with a blockade
of ENaC by VR2 antagonism. Our findings are in agree-
ment with previous clinical studies of the effect of V2R
agonism on sodium excretion by ENaC in patients with
nephrogenic diabetes insipidus (NDI). Administration of
dDAVP induced an antinatriuretic effect in NDI patients
with an intact V2R, but not in those with defective V2R
[32]. This is also in accordance with studies in rats, where a
natriuretic effect was measured after V2R antagonism, but
the aquaretic effect exceeded the natriuretic effect [2,33].
During NO-inhibition, u-ENaCγ decreased after placebo
and increased after tolvaptan. Thus, NO-inhibition antago-
nized the effect of tolvaptan on ENaC. Although the vari-
ation in u-ENaCγ was considerable, this suggests that NO
interferes with the transport via ENaC with an AVP-dependent mechanism, supporting the assumption that the
AVP-cAMP pathway of ENaC regulation is relevant for so-
dium homeostasis in humans [28,32]. However, the de-
crease in sodium reabsorption after L-NMMA was not
mediated by a reduced transport via ENaC, but must be
due to L-NMMA induced change in tubular sodium ab-
sorption at another location in the nephron.
Vasoactive hormones
We found no differences in PRC, p-Aldo and p-AngII at
baseline in the two treatments, whereas p-AVP increased
approximately 3-fold in response to treatment with tolvap-
tan. Most likely, this rise in endogenous p-AVP is a com-
pensatory release of the hormone in response to the rise
in p-osmolality induced by V2R antagonism [34]. During
L-NMMA infusion, PRC fell after placebo and tolvaptan
treatment, whereas p-ANG.II tended to fall after both
treatment, but only significantly in the tolvaptan group.
This is in good agreement with previous results from our
group [9]. P-AVP remained unchanged during L-NMMA
infusion in both treatment groups. Thus, NO does not
seem to have a regulatory effect on the release of AVP.
Central and brachial blood pressure
We observed no changes in bBP and cBP during treat-
ment with tolvaptan despite of the increase in p-AVP in
the tolvaptan group. The effect of AVP on BP is mediated
Table 6 Effect of tolvaptan at baseline and during
inhibition of the nitric oxide system on pulse wave
velocity (PWV), augmentation index (AI), central
diastolic and systolic blood pressure (CBDP and CSBP) in
a randomized, placebo-controlled, double-blind,
crossover study of 19 healthy subjects
Periods Baseline L-NMMA
PWV(m/s)
Placebo 5.3 ± 0.7 5.5 ± 0.5
Tolvaptan 5.3 ± 0.6 5.6 ± 0.7*
p (paired t-test, between) 0.652 0.929
AI
Placebo 0.0 ± 18.7 3.7 ± 18.7
Tolvaptan 1.2 ± 18.3 7.2 ± 17.5*
p (paired t-test, between) 0.646 0.064
CSBP
Placebo 100 ± 7 105 ± 4
Tolvaptan 100 ± 4 107 ± 7*
p (paired t-test, between) 0.871 0.351
CDBP
Placebo 66 ± 12 70 ± 8*
Tolvaptan 64 ± 5 68 ± 8*
p (Wilcoxon signed rank test, between) 0.440 0.622
Data are shown as mean with ± SD or medians with ± interquartile range.
Paired t-test or Wilcoxon signed rank test was used for comparison within (*)
treatment group at baseline vs during infusion period 90–150 min, and at
baseline vs post infusion period 150 – 210 min. *p < 0.05.
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increases BP by a direct effect on vascular smooth muscle
cells, by which AVP stimulates vasoconstriction and in-
creases BP [2]. It is well documented that treatment with
V2 receptor antagonists causes compensatory increase in
the plasma concentration of vasopressin, which stimulates
the V1a receptors in the vascular smooth muscle cells and
thus affect central and peripheral hemodynamics [2]. Our
study is the first to measure both bBP and cBP during
V2R antagonism before, during and after inhibition of sys-
temic NO synthesis in healthy subjects. Applanation to-
nometry was performed under standardized conditions.
The method is described and evaluated elsewhere [35].
We showed that a 3-fold increase in AVP was not suffi-
cient to increase BP via an activation of V1aR, which is
consistent with previous studies [2]. However, pulse rate
values were approximately 2 beats per minute lower in the
tolvaptan group compared to the placebo group. Most
likely, this slight decrease in pulse rate is due to increased
baroreceptor sensitivity exerted by AVP [36,37]. However
this had no net effect on BP. L-NMMA infusion caused an
increase in bBP and cBP to the same extent during both
treatments. The results are in agreement with the results
recently reported by our group [9] on the effect onsystemic NO inhibition on BP. Thus, in the given dose of
tolvaptan, no effect is measured on bBP and cBP.
Plasma levels of sodium, potassium and osmolality
We found significantly higher p-Na, p-K and p-osmolality
in baseline during treatment with tolvaptan. The response
is in agreement with previous clinical studies [12,17,33].
The SALT [17] investigators have demonstrated that serum
sodium concentration was significantly higher within
8 hours after administration of tolvaptan 15 mg compared
to placebo. It should be noticed that their study was con-
ducted in patients with hypervolemic and euvolemic hypo-
natremia. In response to NO inhibition, p-osm and p-K did
not change. In contrast, p-Na decreased in both treatment
groups in the last 30 minutes of L-NMMA infusion. It is
easily explained by the decrease of UO, CH2O and u-Na. Re-
cently, our group reported similar results during L-NMMA
infusion in healthy subjects [9].
Strengths and limitations
The major strength of the present study was the design as
a randomized, double-blinded, placebo-controlled cross-
over trial in healthy subjects. Diet, sodium and fluid intake
were predefined and controlled during the study to avoid
confounding of the results. It is a weakness of the study that
we did not measure total plasma or urine nitrite and nitrate
as indices of NO synthesis to ensure abrogated systemic
NO production. However, during L-NMMA infusion we
measured an increase in mean arterial blood pressure and a
decrease in GFR, UO, CH2O, u-AQP2 and FENa which
clearly indicated NO inhibition.
Conclusion
During baseline conditions, tolvaptan increased renal
water excretion. During NO-inhibition, the more pro-
nounced reduction in renal water excretion after tolvaptan
than after placebo indicates that NO promotes renal water
excretion in the principal cells by at least a partly an AVP-
dependent mechanism. The lack of decrease in u-AQP2
by tolvaptan could be explained by a counteracting effect
of a three-fold increase in plasma vasopressin. The antag-
onizing effect of NO-inhibition on u-ENaC suggests that
NO interferes with the transport via ENaC by an AVP-
dependent mechanism.
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